Huichun Zhan, MD, MS
Attending Physician, Northport VA Medical Center
Associate Professor, Stony Brook University
Lab Location: Health Sciences Tower, 15th Floor, Room 89
Associate Professor of Medicine
- Hematology-oncology fellowship, The Johns Hopkins University School of Medicine
- Internal Medicine, Albert Einstein College of Medicine at Long Island Jewish Medical Center
- M.D., Peking Union Medical College, Beijing, China
- M.S., Cornell University Weill Graduate School of Medical Sciences, New York, NY
- Polycythemia vera
- Essential thrombocythemia
- Primary myelofibrosis
- Hematopoietic stem cell biology
- Hematopoietic microenvironment
- Cardiovascular diseases in hematologic disorders
The Zhan lab focuses on the pathogenesis and treatment of myeloproliferative neoplasms (MPNs). The MPNs are clonal stem cell disorders characterized by hematopoietic stem cell expansion and overproduction of mature blood cells. Patients with MPNs suffer from many debilitating complications such as leukemia transformation and arterial or venous thrombosis, with cardiovascular events being the leading cause of morbidity and mortality in these patients. The acquired kinase mutation JAK2V617F plays a central role in these disorders. Mechanisms responsible for the neoplastic stem cell expansion and hypercoagulability are not fully understood, limiting the effectiveness of current treatment. Our lab investigates the physiological effects and molecular mechanisms by which the JAK2V617F mutation alters endothelial cell and megakaryocyte function in the hematopoietic microenvironment to promote cancer stem cell expansion, and in the general vasculature to affect hemostasis and thrombosis in patients with MPNs. The ultimate goal of our research is to understand the fundamental principles of stem cell biology and develop more effective therapies for patients with MPNs and other hematologic malignancies.
- Zhang H, Castiglione M, Zheng L, Zhan H. Cell competition between wild-type and JAK2V617F mutant cells prevents disease relapse after stem cell transplantation in a murine model of myeloproliferative ne oplasm. (under review)
- Zhang H, Yeware A, Lee S, Zhan H. A murine model with JAK2V617F expression in both hematopoietic cells and vascular endothelial cells recapitulates the key features of human myeloproliferative neoplasm (under review)
- Lee S, Wong H, Castiglione M, Murphy M, Kaushansky K, Zhan H. JAK2V617F mutant megakaryocytes contribute to hematopoietic aging in a murine model of myeloproliferative neoplasm. (under review)
- Castiglione M, Zhang H, Kaushansky K, Zhan H. Cell competition between wild-type and JAK2V617F mutant cells in a murine model of a myeloproliferative neoplasm. Experimental Hematology. 2021.
- Mazzeo C, Quan M, Wong H, Castiglione M, Kaushansky K, Zhan H. JAK2V617F mutant endothelial cells promote neoplastic hematopoiesis in a mixed vascular microenvironment. Blood Cells, Molecules and Diseases. 2021.
- Melissa Castiglione,Ya-Ping Jiang, Christopher Mazzeo, Juei-Suei Chen, Kenneth Kaushansky, Wei Yin, Richard Z. Lin, Haoyi Zheng, Huichun Zhan. Endothelial JAK2V617F mutation leads to thrombosis, vasculopathy, and cardiomyopathy in a murine model of myeloproliferative neoplasm. Journal of Thrombosis and Haemostasis. 2020 Sep 13. doi: 10.1111/jth.15095.
- Yu Zhang, Chi Hua Sarah Lin, Kenneth Kaushansky, Huichun Zhan. JAK2V617F Megakaryocytes Promote Hematopoietic Stem Cell Expansion in Mice through Thrombopoietin/MPL signaling.Stem Cells 2018
- Chi Hua Sarah Lin, Yu Zhang, Kenneth Kaushansky, Huichun Zhan. JAK2V617F-bearing Vascular Niche Enhances Malignant Hematopoietic Regeneration Following Radiation Injury. 2018 Haematologica doi: 10.3324 /haematol.2017.185736
- Huichun Zhan, Chi Hua Sarah Lin, Yarden Segal, Kenneth Kaushansky. The JAK2V617F-bearing Vascular Niche Promotes Clonal Expansion in Myeloproliferative Neoplasms. Leukemia.2017 doi: 10.1038/leu.2017.233.
- Chi Hua Sarah Lin, Kenneth Kaushansky, Huichun Zhan. JAK2V617F-mutant Vascular Niche Contributes to JAK2V617F Clonal Expansion in Myeloproliferative Neoplasms. Blood Cells, Molecules, and Diseases 2016 Nov; 62:42-48. doi: 10.1016/j.bcmd.2016.09.004.
- Huichun Zhan, Yupo Ma, Chi Hua Sarah Lin, Kenneth Kaushansky. JAK2V617F-mutant Megakaryocytes Contribute to Stem Cell Expansion in Myeloproliferative Syndromes. Leukemia 2016 May 2. doi: 10.1038/leu.2016.114.
- Huichun Zhan, Kristen Ciano, Katherine Dong, Stanley Zucker. Targeting Glutamine Metabolism in Myeloproliferative Neoplasms. Blood Cells, Molecules, and Diseases 2015 Oct; 55(3): 241-7.
- Huichun Zhan, Christopher Cardozo, Azra Raza. MciroRNAs in Myeloproliferative Neoplasms. British Journal of Haematology 2013 161(4): 471-83.
- Huichun Zhan, Christopher Cardozo, Wayne Yu, Antai Wang, Alison Moliterno, Chi Dang, Jerry Spivak. MicroRNA Deregulation in Polycythemia Vera and Essential Thrombocythemia Patients. Blood Cells, Molecules, and Diseases 2013 Mar; 50(3): 190-5.
- Zhaohui Ye*, Huichun Zhan*, Prashant Mali, Sarah Dowey, Yoon-Young Jang, Chi V. Dang, Jerry L. Spivak, Alison R. Moliterno, and Linzhao Cheng. Derivation of human iPS cells from blood cells of patients with acquired blood disorders. Blood 2009 Dec; 114(27):5473-5480.
- Huichun Zhan, Jerry Spivak. The Diagnosis and Management of Polycythemia Vera, Essential Thrombocytosis and Primary Myelofibrosis in the JAK2 V617F Era. Clinical Advances in Hematology and Oncology. 2009 May; 7(5): 334-42.
- Huichun Zhan, Michael Streiff, Karen King, Jodi Segal. Thrombotic Thrombocytopenic Purpura at Johns Hopkins from 1992 to 2008: Clinical Outcomes and Risk Factors for Relapse. Transfusion. 2009.
- Huichun Zhan, Lorraine J. Gudas, Dean Bok, Robert Rando, David M. Nanus, and Satish K. Tickoo. Differential Expression of the Enzyme Lecithin: Retinol Acyl Transferase in Subtypes of Human Renal Cancer and Normal Kidney. Clinical Cancer Research Oct.15 2003; 9 (13).
- Huichun Zhan, Depei Liu. Insulator: From Chromatin Domain Boundary to Gene Regulation. Human Genetics Nov. 2001; 109(5): 471-8.